{"analyses":[{"ciPctValue":"95","groupDescription":"Percentage change from baseline to Day 14","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"Wilcoxon (Mann-Whitney)","testedNonInferiority":false},{"ciPctValue":"95","groupDescription":"Percentage change from baseline to Day 14","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"Wilcoxon (Mann-Whitney)","testedNonInferiority":false},{"ciPctValue":"95","groupDescription":"Percentage change from baseline to Day 28","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"Wilcoxon (Mann-Whitney)","testedNonInferiority":false},{"ciPctValue":"95","groupDescription":"Percentage change from baseline to Day 28","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalMethod":"Wilcoxon (Mann-Whitney)","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-77.8","upperLimit":"-40.8","value":"-64.6"},{"groupId":"OG001","lowerLimit":"-77.1","upperLimit":"-48.4","value":"-63.4"},{"groupId":"OG002","lowerLimit":"-35.5","upperLimit":"-5.2","value":"-17.9"}]}],"title":"Day 14"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-91.4","upperLimit":"-68.3","value":"-82.3"},{"groupId":"OG001","lowerLimit":"-91.6","upperLimit":"-73.2","value":"-84.9"},{"groupId":"OG002","lowerLimit":"-81.3","upperLimit":"-47.7","value":"-66.7"}]}],"title":"Day 28"}],"denoms":[{"counts":[{"groupId":"OG000","value":"202"},{"groupId":"OG001","value":"207"},{"groupId":"OG002","value":"201"}],"units":"Participants"}],"description":"Percentage change from Baseline to Day 14 and Day 28 in prostate-specific antigen, which is a clinically important biological marker for treatment effect and prostate cancer progression.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days.","id":"OG000","title":"Degarelix 240/160 mg"},{"description":"Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days.","id":"OG001","title":"Degarelix 240/80 mg"},{"description":"Lupron Depot 7.5 mg IM (in the muscle) every 28 days starting at day 0.","id":"OG002","title":"Leuprolide 7.5 mg"}],"paramType":"MEDIAN","populationDescription":"ITT population.","reportingStatus":"POSTED","timeFrame":"Days 14 and 28","title":"Percentage Change in Prostate-specific Antigen From Baseline to Day 14 and Day 28","type":"SECONDARY","unitOfMeasure":"percent change"}